# Study of Oral Epigallocatechin-3-gallate (EGCG) in IPF Patients

> **NCT05195918** · PHASE1 · COMPLETED · sponsor: **Hal Chapman** · enrollment: 50 (actual)

## Conditions studied

- Idiopathic Pulmonary Fibrosis

## Interventions

- **COMBINATION_PRODUCT:** EGCG 300 mg + Nintedanib
- **COMBINATION_PRODUCT:** EGCG 300 mg + Pirfenidone
- **COMBINATION_PRODUCT:** Placebo 2 capsules + Nintedanib or Pirfenidone
- **COMBINATION_PRODUCT:** EGCG 600 mg + Nintedanib
- **COMBINATION_PRODUCT:** EGCG 600 mg + Pirfenidone
- **COMBINATION_PRODUCT:** Placebo 4 capsules + Nintedanib or Pirfenidone

## Key facts

- **NCT ID:** NCT05195918
- **Lead sponsor:** Hal Chapman
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-08-24
- **Primary completion:** 2026-03-19
- **Final completion:** 2026-03-19
- **Target enrollment:** 50 (ACTUAL)
- **Last updated:** 2026-04-14

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05195918

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05195918, "Study of Oral Epigallocatechin-3-gallate (EGCG) in IPF Patients". Retrieved via AI Analytics 2026-07-17 from https://api.ai-analytics.org/clinical/NCT05195918. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*